Detection of EGFR-TK domain-activating mutations in NSCLC with generic PCR-based methods

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 3, 2015, Pages 163-171

  Shahi, Rajendra B ^a   De Brakeleer, Sylvia ^a   De Grève, Jacques ^a   Geers, Caroline ^b   In't Veld, Peter ^b   Teugels, Erik ^a  

^a Oncologisch Centrum   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

DGGE; EGFR mutation; NSCLC; PNA; real time PCR

Indexed keywords

DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GENOMIC DNA; PEPTIDE NUCLEIC ACID; EGFR PROTEIN, HUMAN;

ALLELE; CANCER CELL CULTURE; DENATURING GRADIENT GEL ELECTROPHORESIS; EXON; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SOMATIC MUTATION; CLINICAL TRIAL; ENZYME ACTIVATION; FEMALE; GENETICS; LUNG TUMOR; MALE; METABOLISM; MULTICENTER STUDY; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84925862743     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PDM.0000000000000035     Document Type: Review

References (39)

1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4: 361-370
2. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003; 284: 99-110
3. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003; 284: 31-53
4. Hynes NE, Horsch K, Olayioye MA, et al. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer. 2001; 8: 151-159
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101: 13306-13311
8. Croce CM. Oncogenes and cancer. N Engl J Med. 2008; 358: 502-511
9. Savic S, Tapia C, Grilli B, et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of nonsmall-cell lung cancers. Br J Cancer. 2008; 98: 154-160
10. Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 2006; 97: 642-648
11. Endo K, Konishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer. 2005; 50: 375-384
12. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005; 11: 2879-2882
13. Soh J, Toyooka S, Aoe K, et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer. 2006; 119: 2353-2358
14. Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2010; 126: 651-655
15. Kawahara A, Azuma K, Sumi A, et al. Identification of non-smallcell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer. 2011; 74: 35-40
16. Miyamae Y, Shimizu K, Hirato J, et al. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep. 2011; 25: 921-928
17. Oh JE, An CH, Yoo NJ, et al. Detection of low-level EGFR T790M mutation in lung cancer tissues. APMIS. 2011; 119: 403-411
18. Ono Y, Toyota Y, Toyoshima A, et al. Antitumor effects of gefitinib for metastatic brain tumors from lung carcinomas with EGFR mutation. No Shinkei Geka. 2011; 39: 569-574
19. Han HS, Lim SN, An JY, et al. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. J Thorac Oncol. 2012; 7: 355-364
20. Ikeda T, Nakamura Y, Yamaguchi H, et al. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2012; 13: 369-374
21. Kawahara A, Taira T, Azuma K, et al. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer. 2012; 78: 39-44
22. Kim HJ, Lee KY, Kim YC, et al. Detection and comparison of peptide nucleic acid-mediated real-Time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer. 2012; 75: 321-325
23. Yamada N, Oizumi S, Asahina H, et al. The Peptide nucleic Acidlocked nucleic Acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations in bronchoscopic cytological specimens of non-small cell lung cancer. Oncology. 2012; 82: 341-346
24. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005; 65: 7276-7282
25. Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res. 2006; 12: 43-48
26. Cohen V, Agulnik JS, Jarry J, et al. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer. 2006; 107: 2858-2865
27. Janne PA, Borras AM, Kuang Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res. 2006; 12(pt 1): 751-758
28. Cushman-Vokoun AM, Crowley AM, Rapp SA, et al. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer. Am J Clin Pathol. 2013; 140: 7-19
29. Akca H, Demiray A, Yaren A, et al. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genet. 2013; 206: 73-80
30. Lee HJ, Xu X, Kim H, et al. Comparison of direct sequencing, PNA clamping-real time polymerase chain reaction, and pyrosequencing methods for the detection of EGFR mutations in non-small cell lung carcinoma and the correlation with clinical responses to EGFR tyrosine kinase inhibitor treatment. Korean J Pathol. 2013; 47: 52-60
31. Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol. 2006; 126: 608-615
32. Kawada I, Soejima K, Watanabe H, et al. An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. J Thorac Oncol. 2008; 3: 1096-1103
33. Yung TK, Chan KC, Mok TS, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009; 15: 2076-2084
34. Li J, Makrigiorgos GM. COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. Biochem Soc Trans. 2009; 37(Pt 2): 427-432
35. Kristensen LS, Andersen GB, Hager H, et al. Competitive amplification of differentially melting amplicons (CADMA) enables sensitive and direct detection of all mutation types by highresolution melting analysis. Hum Mutat. 2012; 33: 264-271
36. De Grève JL, Van Meerbeeck J, Vansteenkiste J, et al. Prospective evaluation of first-line tyrosine kinase inhibition with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) harbouring a mutant EGFR gene (FIELT study). J Thorac Oncol. 2007; 2: S712
37. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361: 958-967
38. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7: 169-181
39. Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004; 91: 355-358